Clinical use of photobiomodulation for the prevention and treatment of oral mucositis: the real-life experience of MASCC/ISOO members.
Cancer
Effective
Laser
Oral mucositis
Pain
Photobiomodulation
Prevention
Treatment
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
21 Jul 2023
21 Jul 2023
Historique:
received:
22
05
2023
accepted:
28
06
2023
medline:
24
7
2023
pubmed:
22
7
2023
entrez:
21
7
2023
Statut:
epublish
Résumé
To assess clinical use and patient outcome of photobiomodulation (PBM) for oral mucositis (OM) prevention and treatment among specialized practitioners. A poll was emailed to the members of the Mucositis Study Group of MASCC/ISOO. The PBM parameters used by the respondents were analyzed using exploratory statistical methods to identify combinations of PBM parameters (patterns) that characterize the variance in the protocols (principal component analysis). Responses were received from 101 MSG members, with 78 providing analyzable data. Most of the responders were dental practitioners or oral medicine specialists. PBM was used by 59% of the responders for OM or targeted therapy stomatitis. Technical parameters varied widely. Most responders used wavelengths ∼650 nm intra-orally. The spot-size and distance from the tissue were the main factors driving the variation. All PBM users noted that PBM relieved pain, either immediately or a delayed effect. High likelihood of pain relief (measured as responder's report of pain relief in 67-100% of patients) was reported by 22% and 19% of PBM users for immediate pain relief and delayed pain relief, respectively. The most common reported barriers to using PBM were financial considerations, time constraints, lack of training or experience and concern about the potential for malignant transformation or increased risk of cancer recurrence. The use of PBM for OM prevention or treatment is in early phases of adoption in practices, facing some obstacles to implement it. A wide variation in technical parameters was found. Nonetheless, responses indicate that PBM provided pain relief.
Identifiants
pubmed: 37479822
doi: 10.1007/s00520-023-07919-9
pii: 10.1007/s00520-023-07919-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
481Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, Bowen J, Gibson R, Saunders DP, Zadik Y, Ariyawardana A, Correa ME, Ranna V, Bossi P (2020) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 126:4423–4431
doi: 10.1002/cncr.33100
pubmed: 32786044
Elad S, Yarom N, Zadik Y, Kuten-Shorrer M, Sonis ST (2021) The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies. CA Cancer J Clin 29:21704
Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ (2000) Patient reports of complications of bone marrow transplantation. Support Care Cancer 8:33–39
doi: 10.1007/s005209900095
pubmed: 10650895
Rose-Ped AM, Bellm LA, Epstein JB, Trotti A, Gwede C, Fuchs HJ (2002) Complications of radiation therapy for head and neck cancers. The patient’s perspective. Cancer Nurs 25:461–467
doi: 10.1097/00002820-200212000-00010
pubmed: 12464838
Haverman TM, Raber-Durlacher JE, Rademacher WM, Vokurka S, Epstein JB, Huisman C, Hazenberg MD, de Soet JJ, de Lange J, Rozema FR (2014) Oral complications in hematopoietic stem cell recipients: the role of inflammation. Mediators Inflamm 378281:10
Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, Hayden V, Eilers J, Epstein JB, LeVeque FG, Miller C, Peterson DE, Schubert MM, Spijkervet FK, Horowitz M (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19:2201–2205
doi: 10.1200/JCO.2001.19.8.2201
pubmed: 11304772
Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB (2003) The burdens of cancer therapy: clinical and economic outcomes of chemotherapy‐induced mucositis. Cancer: Interdisciplinary International Journal of the American Cancer Society 98:1531–1539
doi: 10.1002/cncr.11671
Hamblin MR (2016) Photobiomodulation or low-level laser therapy. J Biophotonics 9:1122–1124
doi: 10.1002/jbio.201670113
pubmed: 27973730
pmcid: 5215795
Hamblin MR (2017) Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys 4:337–361
doi: 10.3934/biophy.2017.3.337
pubmed: 28748217
pmcid: 5523874
Zadik Y, Arany PR, Fregnani ER, Bossi P, Antunes HS, Bensadoun RJ, Gueiros LA, Majorana A, Nair RG, Ranna V, Tissing WJE, Vaddi A, Lubart R, Migliorati CA, Lalla RV, Cheng KKF, Elad S (2019) Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer 27:3969–3983
doi: 10.1007/s00520-019-04890-2
pubmed: 31286228
Elad S, Arany P, Bensadoun RJ, Epstein JB, Barasch A, Raber-Durlacher J (2018) Photobiomodulation therapy in the management of oral mucositis: search for the optimal clinical treatment parameters. Support Care Cancer 26:3319–3321
doi: 10.1007/s00520-018-4262-6
pubmed: 29789949
Sandoval RL, Koga DH, Buloto LS, Suzuki R, Dib LL (2003) Management of chemo- and radiotherapy induced oral mucositis with low-energy laser: initial results of A.C. Camargo Hospital. J Appl Oral Sci 11:337–341
doi: 10.1590/S1678-77572003000400012
pubmed: 21394411
da Silva BM, Prosdócimo ML, Gasparini LR, de Araujo MR, Amenábar JM (2022) Most used photobiomodulation dosimetry parameters to treat oral mucositis after preconditioning for hematopoietic stem cell transplantation: systematic review and meta-analysis. Support Care Cancer 30:3721–3732
doi: 10.1007/s00520-022-06817-w
pubmed: 35013780
Konishi T (2015) Principal component analysis for designed experiments. BMC Bioinform 18:1471–2105
Patel P, Robinson PD, Baggott C, Gibson P, Ljungman G, Massey N, Ottaviani G, Phillips R, Revon-Rivière G, Treister N, White M, Cabral S, Dupuis L, Sung L (2021) Clinical practice guideline for the prevention of oral and oropharyngeal mucositis in pediatric cancer and hematopoietic stem cell transplant patients: 2021 update. Eur J Cancer 154:92–101
doi: 10.1016/j.ejca.2021.05.013
pubmed: 34252760
Robijns J, Nair RG, Lodewijckx J, Arany P, Barasch A, Bjordal JM, Bossi P, Chilles A, Corby PM, Epstein JB (2022) Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper. Front Oncol 12:927685
doi: 10.3389/fonc.2022.927685
pubmed: 36110957
pmcid: 9468822
Gavish L, Zadik Y, Raizman R (2021) Supportive care of cancer patients with a self-applied photobiomodulation device: a case series. Support Care Cancer 29:4743–4749
doi: 10.1007/s00520-021-06027-w
pubmed: 33517481
pmcid: 7847302
Zecha JA, Raber-Durlacher JE, Nair RG, Epstein JB, Elad S, Hamblin MR, Barasch A, Migliorati CA, Milstein DM, Genot MT, Lansaat L, van der Brink R, Arnabat-Dominguez J, van der Molen L, Jacobi I, van Diessen J, de Lange J, Smeele LE, Schubert MM, Bensadoun RJ (2016) Low-level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 2: proposed applications and treatment protocols. Support Care Cancer 24:2793–2805
doi: 10.1007/s00520-016-3153-y
pubmed: 26984249
pmcid: 4846551
Zadik Y (2019) Photobiomodulation for the palliation of oral mucositis in cancer patients: the future is here. Future Oncol 15(32):3647–3649
doi: 10.2217/fon-2019-0461
pubmed: 31650847